Torex Gold Resources, Kinaxis Inc and More at 52-week Highs & Lows (Mar 15-21)

Peak valuation now. He models $60, today's price. Would buy at $35. It's cyclical which will decline in a recession.

It has always been over-leveraged and is still that way today. It has had to dump positions just to stay afloat. It is in a decent place with the jet business but not enough to warrant buying it.

Question was on comparing Aecon to Bird. They have good yields of 5%. Backlogs are not as meaningful in this environment. Construction costs are up and there are still supply chain issues. Bird is in a better situation since it has fewer fixed costs.

Boring business (utility poles and railway ties). Very strong dividend. Has been performing well in terms of business. Good ling term prospects (infrastructure growth will require products.

Volatile. Not easy to understand. Engineered materials mainly for the solar industry. They've diversified. A recent acquisition may be transformative, wait and see. Hold if you own it. He's revisiting it. He prefers NEO, as a cheap way to play the EV market.

(A Top Pick Nov 11/21, Down 21.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with WJX has triggered its stop at $22. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

$8.8 billion in debt but shareholder equity is $6 billion, so there is not a lot of debt. He models $113.35. Hold this in a recession or bear market, but buy this below $134.

Are in a great space, a growth area in industrials. But their debt is too high and explains their volatility. They grow by acquiring, which adds to debt. Managed well, though.

Likes all transportation, especially this one.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Solid M&A pipeline. Trades at a premium. Continued growth during COVID. Tailwinds from global trade complexities.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. 50% increase in workforce; positive sign. Reduced margins expected to normalize. Backlog remains healthy. Fair valuation compared to software peers.

Very affordable tech name.Company has done very good job building shareholder value.Trading around 16X 2024 EPS.Wait to buy shares on weakness.

(A Top Pick Feb 16/22, Down 3%) Inexpensive at 9-10x earnings. Fantastic dividend yield, almost 6%. Peers are pursuing EMs. GWO is doing the opposite, focusing on mature markets. Very well run. Conservative, nice total return.

A good dividend and balance sheet is strong. Cash flow, too. Most of your return will come from the dividend. The problem is that they're in a secular growth industry anymore, not like the 1990s or the early 2000s, and it's being disrupted by fintech. IGM is fine, but will not appreciate much.

Fundamentally a strong company.Recent increase in shares makes name expensive.Waiting for shares to fall before buying.Long term is a good investment.Very strong assets and management. 

Low valuation for in-home medical services company.Does not own shares in the company, but has owned in the past.Looking into buying shares in the future.Management team has done great job growing company.

(A Top Pick Jan 05/23, Up 4%) Pretty strong dividend, which he's bullish on right now. One of the best charts in the gold space, if not the best. Doesn't hesitate to recommend.

(A Top Pick Feb 07/22, Up 17%) One mine is winding down, but another is ramping up production. Well funded, cash on the balance sheet. No debt. Trading at 3-4x operating cashflow. He took profits when it ran up.

Mostly early stage exploration projects. Good diversification. Likes their Copper Canyon project which is part of the overall Galore Creek project.

They have a large Brazilian gold deposit. The problem here are indigenous people challenges there and a government contract that pays out a crazy amount to the managers. This payout is not aligned to the shareholders' interests. Then again, it's a cheap stock vs. gold in the ground.

Likes the managers, but concerned with the topography. A decent-sized gold project. A good speculation.

It's a 10 cent stock, when even the big companies aren't doing well. If you like it, sure go ahead. But there's nothing he can add.

A great young team. It’s too early to say what sort of success they’re going to have. Their early implementation of their royalty/streaming business plan has been absolutely flawless, but you have to understand that it is a new company/young team risk.

(Market Call Minute.) Great execution with a $500 million market cap. Thinks it is ahead of itself. It is expensive.

Chart shows a up pattern on the beginning of the year. Even though it had a nasty day today, the uptrend has not been violated. Has to get through about the $1.25 area before it can be considered a breakout. If you know the fundamentals and this matches them, it could be okay. (See Top…

A very large, low grade deposit. It has a little over 1 million ounces M&I, and probably 3 in inferred resources. A real, sketchy sort of deposit in that the mineralization is spotty. If you were to try to mine this as an open pit, your waste to ore ratio would be extremely high, especially…

Sees no change to the dividend theory. The 3 Irish business millionaires actually control the company and are holding it long-term for the dividends. The company has some costs going on disadvantaging it. The diamond sector itself has not produced really stellar performance. This is a “wait and see”.

Has a silver discovery in the Durango area of Mexico. It is a joint venture with Orex (REX-X) earning in. They are carried for 35% once Orex has earned in. A very interesting project. They drilled into an alteration zone and hit good mineralization which is fairly consistent and looks like it is averaging 2-250…

He's learning as much as he can about this stock. He's nervous about little markets with great, big technogical promise. This could be a good market performer this year. Perhaps own this for the long-term, but knuckle down and learn what this company does with aluminum alloy technology.

(Top Pick Jul 13/11, Down 8.69%) Funding issue. Venture is down about 38%. Exploration companies have come off the most. Smaller company that didn’t have a lot of cash. Two days ago they came up with a huge whole with 1.3 grams. If you have a long-term perspective, wait until they do their funding.

It got stuck above $30 and is now building a nice base. He likes this.

Underlying business still working fantastically. Comes down to market size and market cap. Trades at around 1x sales, whereas peers are around 3x sales. As they continue to grow organically and by acquisition, revenue keeps going up. Announced NASDAQ listing, which will boost multiple. Acquisition in progress should boost revenue by 35-40%, share price should…

Figured out a way to use an agent to produce CBD in a lab, which will make it cheaper and more consistent. Still rolling it out into the commercial space. The future.

He owned the stock years ago. They dry things like food. They are now getting into the marijuana space. It has done very well lately but if they are going to get meaningful contracts, they are going to do well.

Doesn't know much about this. Shied away from it for now, because it doesn't trade much. Has the potential to be a bigger small-cap healthcare company, an area that he likes.

Lots of opportunity in the US. Guilty of using easy money to build massive facilities. Big writedowns. Big equity offering. Doesn't see an imminent big export market. Longer term potential, but it's an outside probability.

Wellness drives CBD demand and there's more competition entering this space. The CBD market continues to expand into drinks and food. He used to own this, but sees better opportunities. But CWEB is one of the U.S. leaders in this crowded space, so it's okay. You want to be in this space.

(A Top Pick Jan 14/21, Up 35.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with OGI has triggered its stop at $3.00. We recommend covering the balance of the position at this time. When combined with the previous recommendation to cover half the position, this results in a net investment gain over 46%.

Medical robotics? He does not know TMD-T well. He plays the space through and ETF of BOTZ-Q. He prefers ISRG-Q, if you wanted an individual holding.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free

It is the biggest in the Canadian market and is moving into the U.S. market as well. He focuses on the U.S. market. An inventory of cannabis products is building in New York with some of it being the illegal variety.

Going forward, will be a large market for healthcare products. Aging population will ensure demand for products. Vitamins will help aging population. Healthcare will do well in the long term.

Cannabis is such a challenging sector. Has expanded into the U.S. He has great respect for management. It could be a possible takeout target.

This does mobile marketing for big brands, where you use your phone to run loyalty programs and purchase validations. Down 53% in the last year, because it got caught up in the downdraft in the TSX Venture. It would be higher today, except that their financing was the worst kept secret on Bay Street, which…

Balance sheet's come down in 3 steps. After the first 2 steps, the stock doubled, but it was short term and you had to be quick. No guarantees it will happen again a third time. Yesterday's dividend cut may cause a quick pop in the stock.

Longer-term downtrend, the opposite of what the market's a doing in a negative way. It's a big sign that something is not moving in the right direction. Be cautious.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Struggling with broad market weakness. Investors are throwing in the towel. Has to prove it can meet expectations. Turnaround might be taking hold.

(A Top Pick Jan 26/23, Down 10.7%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with CCA has triggered its stop at $61.  To remain disciplined, we recommend covering the position at this time. 

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Has had a good start to the year. UP 19%. Expensive at 17x sales. THey made an acquisition that brought in $24M in revenues. Insiders own 31%. Moving into Europe. Remains speculative but getting interesting. Unlock Premium - Try 5i Free

A small-cap company, not focussed on real estate, managed by Dream Unlimited. Focused on renewable energy and have an interest in the office buildings owned by Dream Office REIT. DRA has a growing land base in the GTA for condo sites. It's trading at a discount to NAV. They've traded a substantial issuer bid to…

(A Top Pick Jan 26/23, Down 7.8%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with AX.UN has triggered its stop at $8.80.  To remain disciplined, we recommend covering the position at this time.  

Likes the sector, lots of runway. Renewable natural gas. Governments are increasing demand. On his radar. Will look at again when risk appetite in the market returns.

It owns medical facilities globally. This includes medical office buildings, hospitals, etc. The balance sheet is a bit stretched along with an 8% yield. Another concern is some cash flow disruption due to not hedging currencies.

Small company, losing money. Data analytics, enterprise software solutions in the financial space. Too tiny for his firm. (Analysts’ price target is $0.52)

Light stands for solar driven lights. The real opportunity is in Africa. It is a relatively illiquid stock.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Recent earnings: EPS was a loss of 7c versus an expected gain of 3.2c. EBITDA did increase 12%, though. Cash flow per share increased 18%. Debt remains high at 2.9X EBITDA, though just within the company's targetted range. A couple of brokers lowered target prices on the results. While a…

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The company reported good sales growth, suggesting good adoption. Results missed estimates by $2M. There is opportunity here but expectations are high. Growing at nearly 50% and no reason for slowing growth. The stock has held well despite the miss. Unlock Premium - Try 5i Free

A smart move to get into beer by buying some brands. True, they are losing money, but this and Canopy are the best in this space.

Would not buy at current share price.Too much investment into the sector will depress prices.Well run company, but saturated market.Strong management.If shares fall under $100, will look into buying. 

We need potash, and demand will spike. Reticent to chase a small name like this. Look to a large cap. He likes NTR, which is reasonably priced, all things considered.

Looking at the chart, pretty big runup since the pandemic. Most energy stocks have had a sideways consolidation over the last year or so. Oil likely to move lower and be in a sideways, choppy trading range. Easy money's been made.

There are aspects that will detract institutional ownership. There are some promotional aspects. The name is cheap and are paying down debt. It is not a name he is looking at. The quantitative and qualitative aspects need to match and for him it does not meet his requirements.

Great energy stock, but seeing better opportunity in other names. Operating in Colombia which has geopolitical risk. Windfall taxes etc.

Allan Tong’s Discover Picks Companies like Polaris trade at high PEs (102.44x), but that’s par for the course. Another caveat is that PIF is a small-cap of only $344 million, so it can be vulnerable to market mood swings—and we’ve had no shortage of that. PIF pays a steady dividend of 5%, which investors can…